Cell and molecular analyses validated that MDM2 is a direct target of MTF2/PRC2 and is upregulated in MTF2-deficient refractory AML, leading to the repression of p53-mediated apoptosis in response to treatment [13]. Here, TP53 is linked to acute myeloid leukemia.